Skip to main content
Farmacosmo logo

Farmacosmo — Investor Relations & Filings

Ticker · ZJ1 ISIN · IT0005487670 LEI · 815600ABEDB6F0BDDE28 XMIL Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2022-04-01 Director's Dealing
Country IT Italy
Listing XMIL ZJ1

About Farmacosmo

https://www.farmacosmo.com/

Farmacosmo is an e-commerce company that operates an online platform for health, beauty, and personal care products. The company's core business is the online sale of a broad range of items, including parapharmaceuticals, supplements, cosmetics, personal care products, baby supplies, and pet care essentials. Managing its platform in-house, Farmacosmo offers a catalog of over 80,000 products from various brands. The company aims to provide a comprehensive wellness destination by combining the offerings of a pharmacy and a cosmetics retailer, supported by expert advice from professionals.

Recent filings

Filing Released Lang Actions
Farmacosmo - Fabio De Concilio (MAR) - Modello di notifica e di comunicazione al pubblico delle operazioni
Director's Dealing Classification · 100% confidence The document is titled in Italian as a 'Modello di notifica e di comunicazione al pubblico delle operazioni effettuate da persone che esercitano funzioni di amministrazione, di controllo o di direzione e da persone a loro strettamente associate' (Notification model and public communication of transactions carried out by persons discharging managerial responsibilities and persons closely associated with them). This structure, detailing transactions (Cessione di azioni - share sale, Opzione di prestito titoli - securities lending option) by a senior manager (Amministratore Delegato - CEO) involving company shares (Farmacosmo S.p.A.), is characteristic of insider trading or director's dealing disclosures required by market regulators (like CONSOB in Italy, which often uses similar formats for MAR compliance). This directly maps to the 'Director's Dealing' category. Filing Type Code: DIRS (Director's Dealing).
2022-04-01 Italian
Farmacosmo - Bartoli (TUF) Modello di notifica e di comunicazione al pubblico
Major Shareholding Notification Classification · 99% confidence The document is titled "Modello di notifica e di comunicazione al pubblico delle operazioni effettuate da chiunque detiene azioni in misura almeno pari al 10 per cento del capitale sociale..." (Notification model and public communication of transactions carried out by anyone holding shares of at least 10 percent of the share capital...). This clearly indicates a mandatory disclosure regarding significant shareholdings and transactions by an insider or major shareholder. The content details 'Operazione 1' (Cessione di azioni - Share transfer) and 'Operazione 2' (Opzione di prestito titoli - Securities lending option) involving the transfer of shares by an individual holding over 10% of the issuer (Farmacosmo S.p.A.). This aligns perfectly with the definition of Director's Dealing or Insider Transaction reporting, which is categorized as 'Director's Dealing' (DIRS) in the provided schema, as it reports personal share transactions by executives/insiders (or those holding significant stakes).
2022-04-01 Italian
FARMACOSMO: COMUNICAZIONE INTERMEDIA PERIODO DI STABILIZZAZIONE
Capital/Financing Update Classification · 99% confidence The document is a formal communication titled "FARMACOSMO: COMUNICAZIONE INTERMEDIA PERIODO DI STABILIZZAZIONE" (Interim Communication Stabilization Period) dated April 1, 2022. It details transactions conducted by illimity Bank S.p.A. related to the stabilization of Farmacosmo's ordinary shares, referencing EU Regulation 2016/1052. This type of communication, which reports on market stabilization activities following an offering, is a specific type of regulatory disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). Since it reports on specific market/financing activities (stabilization), it fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Given the explicit focus on stabilization operations related to share price management post-offering, 'CAP' (Capital/Financing Update) is the most precise fit among the defined categories, as stabilization is intrinsically linked to the capital market activities surrounding the listing/offering. The document length (6997 chars) is substantial enough that it is not merely an announcement of a report (RPA/RNS fallback), but the report itself detailing the stabilization figures.
2022-04-01 Italian
IL CDA APPROVA I DATI ECONOMICO-FINANZIARI AL 31 DICEMBRE 2021
Earnings Release Classification · 96% confidence The document is a formal communication dated April 1, 2022, titled 'IL CDA APPROVA I DATI ECONOMICO-FINANZIARI AL 31 DICEMBRE 2021' (The Board of Directors approves the economic-financial data as of December 31, 2021). It contains key financial highlights (Revenues, EBITDA, Net Result) for the fiscal year ending December 31, 2021, and includes detailed financial statements (Income Statement and Balance Sheet) as attachments. This content structure—a press release announcing the approval of annual financial results and providing key figures and attached statements—is characteristic of an Earnings Release (ER) or, given the comprehensive nature including the full P&L and Balance Sheet, it strongly suggests the core content of an Annual Report (10-K) or a detailed Interim/Quarterly Report (IR). Since the period covered is the full fiscal year ending December 31, 2021, it relates to the annual results. However, the document itself is a press release format (Informazione Regolamentata) announcing the approval and providing highlights, rather than the full, audited 10-K filing itself. The presence of detailed financial tables and the announcement of the dividend proposal and AGM convocation align closely with the content typically found in an Earnings Release (ER) or a comprehensive report announcement. Given the detailed financial data provided directly in the text, 'ER' (Earnings Release) is the most appropriate classification for this initial announcement of annual results, even though it contains more detail than a typical quarterly ER. If the document were the full statutory filing, it would be 10-K, but this appears to be the market announcement. FY 2021
2022-04-01 Italian
FARMACOSMO: APPROVATO IL CALENDARIO DEGLI EVENTI SOCIETARI 2022
Report Publication Announcement Classification · 99% confidence The document is titled 'FARMACOSMO: APPROVATO IL CALENDARIO DEGLI EVENTI SOCIETARI 2022' (FARMACOSMO: APPROVED THE CALENDAR OF CORPORATE EVENTS 2022). It explicitly states that the Board of Directors approved the calendar of corporate events for 2022, which includes dates for financial report approvals (e.g., 2021 year-end results, Q1 2022 data, H1 2022 results) and the Shareholders' Meeting (Assemblea dei Soci). This type of announcement, which details future scheduled corporate events, is a general regulatory announcement often classified as a Regulatory Filing (RNS) or, more specifically, an announcement about future corporate actions/dates. Since there is no specific category for 'Corporate Event Calendar Approval,' and it is a formal communication to the market regarding future scheduled events, it fits best under the general regulatory announcement category (RNS). It is not a specific report (like 10-K, IR, ER) but an announcement *about* future reports and meetings. The document length is moderate (6980 chars), but the content is purely informational regarding scheduling, not the actual financial data or a full report.
2022-03-31 Italian
Farmacosmo: primo giorno di negoziazioni
Capital/Financing Update Classification · 95% confidence The document is a press release (COMUNICATO STAMPA) detailing the first day of trading (debutto) of the company Farmacosmo on the Euronext Growth Milan market following an IPO. It includes details about the placement price, closing price, market capitalization, and the resulting shareholding structure after the capital increase and share sale. This announcement is a significant corporate action related to financing and capital structure changes, specifically the Initial Public Offering (IPO) and subsequent listing. While it touches upon financing (IPO proceeds), the core event being reported is the successful listing and the immediate post-listing details, including the capital structure update. This fits best under 'Capital/Financing Update' (CAP) as an IPO is the primary financing activity, or potentially 'Regulatory Filings' (RNS) if it were a generic regulatory disclosure. However, given the focus on the successful fundraising and listing mechanics, CAP is the most specific fit among the provided options for an IPO announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR).
2022-03-30 Italian

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.